{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.6197","value":"2.928"},{"groupId":"OG001","spread":"4.1006","value":"5.652"}]}],"title":"Pre-dose (Cmin) (n: 7, 32)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.6842","value":"13.035"},{"groupId":"OG001","spread":"13.3800","value":"22.005"}]}],"title":"2 hours post administration (C2h) (n:10, 43)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"43"}],"units":"Participants"}],"description":"Pre-dose (Cmin) and 2 hours post-dose (C2h) everolimus PK blood samples were collected at Cycle 2 Day 1. Only valid everolimus PK blood samples collected at steady state were used in the analyses.","dispersionType":"Standard Deviation","groups":[{"description":"Oral everolimus of 2.5 mg/day","id":"OG000","title":"Everolimus 2.5 mg"},{"description":"Oral everolimus of 5 mg/day","id":"OG001","title":"Everolimus"}],"paramType":"MEAN","populationDescription":"The Safety Set consisted of all patients who received at least one dose of the study treatment and who had at least one valid post-baseline safety assessment.","reportingStatus":"POSTED","timeFrame":"Cycle 2, Day 1","title":"Everolimus Blood Concentrations by Leading Dose and Time Point","type":"SECONDARY","unitOfMeasure":"ng/ml"}